Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat ...
Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments. Read why I think NVO stock is a hold.
Diabetes patients worry about insulin shortages as Ozempic use skyrockets
The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for ...
Novo Nordisk's semaglutide could also be effective against Alzheimer's
A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...
Pharmacists “desperation” by Novo Nordisk over semaglutide copycat block
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...
NBC New York2d
Healthy Returns: Weight loss, diabetes drugs may reduce alcohol and opioid use
Yet another study shows that blockbuster GLP-1 drugs may offer health benefits beyond diabetes and weight loss. This time, ...